Henry S. Park

Dr. Henry S. Park

Department of Therapeutic Radiology (Radiation Oncology), Yale School of Medicine, New Haven, CT, USA
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2024 in Chest
Verified
Journal Article
Closed access
FDFrank C. Detterbeck
Frank C. Detterbeck
GWGavitt A. Woodard
Gavitt A. Woodard
ABAnna S. Bader
Anna S. Bader
SDSanja Dacic
Sanja Dacic
MGMichael J. Grant
Michael J. Grant
LTLynn T. Tanoue
Lynn T. Tanoue

16 November 2009 in Archives of Surgery
Verified
Journal Article
Open access
PDF file
Henry S. ParkHenry S. Park
Henry S. Park
SRSanziana A. Roman
Sanziana A. Roman
JSJulie Ann Sosa
Julie Ann Sosa
Research from JAMA Surgery — Outcomes From 3144 Adrenalectomies in the United States — Which Matters More, Surgeon Volume or Specialty?

27 December 2011 in Cancer
Verified
Journal Article
Open access
PDF file
DBDaniela L. Buscariollo Bs
Daniela L. Buscariollo Bs
Henry S. ParkHenry S. Park
Henry S. Park
KRKenneth B. Roberts
Kenneth B. Roberts
JYJames B. Yu
James B. Yu
BACKGROUND: Atypical teratoid rhabdoid tumor (ATRT) is a rare central nervous system malignancy with a poor prognosis that affects mostly young children. Although radiotherapy (RT) historically has been delayed in patients aged <3 years, emerging evidence suggests a role for RT to achieve long‐term survivorship. Clinical features and age‐dependent trends of RT use were evaluated for patients with ATRT.METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results database was used to identify 144 patients with ATRT from 1973 to 2008. The primary endpoint was median overall survival (OS). Clinical and treatment variables were assessed for an association with OS using Cox proportional hazards models. Landmark analysis was used to correct for immortal time bias of adjuvant RT.RESULTS: The median age at diagnosis was 1 year (range, 0‐67 years). Gross total resection of the primary tumor was achieved in 39% of patients, and 33% of patients received RT. From 1992 to 2008, RT use increased 2.4‐fold in patients aged ≤3 years. The median OS for was 10 months. In multivariate analyses, metastatic disease (hazard ratio, 2.83; 95% confidence interval, 1.53‐5.23; P = .001) and RT (hazard ratio, 0.10; 95% confidence interval, 0.01‐0.73; P = .02) were identified as independent predictors of survival. Landmark analysis confirmed a robust association between RT use and survival, which was attenuated in patients ages 4 to 17 years compared with younger patients.CONCLUSIONS: The current results indicated that RT may offer a significant survival benefit for patients with ATRT and that patients aged ≤3 years may derive more benefit from initial RT compared with older children. The authors concluded that prospective clinical trials are needed to examine the role of RT in the initial management of ATRT in patients aged <3 years. Cancer 2012. © 2011 American Cancer Society.

1 July 2012 in Current Problems in Cancer
Verified
Journal Article
Closed access
Henry S. ParkHenry S. Park
Henry S. Park
SLShane Lloyd
Shane Lloyd
RDRoy H. Decker
Roy H. Decker
LWLynn D. Wilson
Lynn D. Wilson
JYJames B. Yu
James B. Yu

1 August 2012 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
Henry S. ParkHenry S. Park
Henry S. Park
CGCary P. Gross
Cary P. Gross
DMDenis V. Makarov
Denis V. Makarov
JYJames B. Yu
James B. Yu

14 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RORebecca Kemunto Ogembo
Rebecca Kemunto Ogembo
PGPhilimon Nyakauru Gona
Philimon Nyakauru Gona
ASAlaina J Seymour
Alaina J Seymour
Henry S. ParkHenry S. Park
Henry S. Park
PBPaul A Bain
Paul A Bain
JOJavier Ogembo
Javier Ogembo
Several meta-analyses confirmed the five most prevalent human papillomavirus (HPV) strains in women with and without cervical neoplastic diseases are HPV16, 18, 31, 52, and 58. HPV16/18 are the predominant oncogenic genotypes, causing approximately 70% of global cervical cancer cases. The vast majority of the women studied in previous analyses were from Europe, North America, Asia, and most recently Latin America and the Caribbean. Despite the high burden of cervical cancer morbidity and mortality in Africa, a robust meta-analysis of HPV genotype prevalence and distribution in African women is lacking. We systematically searched 14 major databases from inception to August 2013 without language restriction, following the Meta-Analysis of Observational Studies in Epidemiology and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Seventy-one studies from 23 African countries were identified after screening 1162 citations and data abstracted and study quality appraised from 195 articles. HPV type-specific prevalence and distribution was estimated from 17,273 cases of women with normal cervical cytology; 1019 women with atypical squamous cells of undetermined significance (ASCUS); 1444 women with low-grade squamous intraepithelial lesion (LSIL); 1571 women with high-grade squamous intraepithelial lesion (HSIL); and 4,067 cases of invasive cervical carcinoma (ICC). Overall prevalence of HPV16/18 were 4.4% and 2.8% of women with normal cytology, 12.0% and 4.4% with ASCUS, 14.5% and 10.0% with LSIL, 31.2% and 13.9% with HSIL, and 49.7% and 18.0% with ICC, respectively. Study limitations include the lack of adequate data from Middle and Northern African regions, and variations in the HPV type-specific sensitivity of different genotyping protocols. To our knowledge, this study is the most comprehensive assessment of the overall prevalence and distribution of HPV genotypes in African women with and without different cervical neoplasias. We have established that HPV16/18 account for 67.7% of ICC cases among African women. Based on our findings, we highly recommend the administration of existing prophylactic vaccines to younger women not infected with HPV16/18 and an increase in HPV screening efforts for high-risk genotypes to prevent cervical cancer. Review registration: International Prospective Register of Systematic Reviews CRD42013006558.